Because the activation of protein tyrosine phosphatases could principally reduce the phosphorylation of receptor tyrosine kinases leading to the suppression of cell growth, the forced activation of protein tyrosine phosphatases targeting EGFR and/or HER2 could be new strategy for HER2-positive breast cancer therapies. The gene discussed is ERBB2; the disease is breast cancer.